The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
AstraZeneca breast cancer pill faces review delay from regulators
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Pharmalittle: We're reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
EU and US advisers split over AstraZeneca breast cancer drug
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
